Ispecimen Inc is a biotechnology company focused on enhancing the accessibility of biospecimens for research and clinical purposes. By leveraging advanced technology and an extensive network of biorepositories, Ispecimen facilitates the collection, management, and distribution of human biological samples, thereby accelerating medical research and development. Their platform aims to streamline the process for academia, pharmaceutical companies, and other organizations in need of high-quality biospecimens, ultimately contributing to advancements in personalized medicine and healthcare solutions. Read More
U.S. Markets: Today’s premarket session has seen explosive moves across several small-cap names, driven by takeover bids, AI-powered product launches, e-commerce strength, and blockchain treasury initiatives.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Woburn, Massachusetts--(Newsfile Corp. - September 4, 2025) - iSpecimen Inc. (NASDAQ: ISPC), (the "Company"), a technology-enabled company modernizing the way...
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced...
iSpecimen Inc. (NASDAQ: ISPC ) closed yesterday at $1.16 per share with a market cap of just $6.4 million, based on 5.54 million shares outstanding. On paper, that number looks almost absurd for a company with working revenues, strategic partnerships, and now, a planned $200 million digital treasury.
WOBURN, MA / ACCESS Newswire / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025)
Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens...
That’s the story unfolding right now around iSpecimen Inc. (NASDAQ: ISPC), a microcap life sciences company that just made one of the boldest capital strategy announcements in recent memory. On Wednesday evening—after the market closed—iSpecimen unveiled its plan to establish a $200 million digital treasury focused on capital preservation, liquidity, and long-term growth.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
WOBURN, MA / ACCESS Newswire / August 8, 2025 / Occasionally, the market reacts in ways that don't immediately align with the news. That seems to be the case right now with iSpecimen Inc. (NASDAQ:ISPC), following a major strategic announcement that arrived after Wednesday's close.
